Stanford scientists have identified a novel brain-targeted peptide called BRP that suppresses appetite as effectively as GLP-1 drugs but without nausea or muscle loss in animal models.
A research team at Stanford Medicine has uncovered a small peptide molecule dubbed BRP that could represent a major leap forward in weight-loss pharmacology. Unlike current GLP-1 receptor agonists such as semaglutide, BRP appears to act directly on the brain's appetite-control center without triggering the gastrointestinal side effects that cause many patients to discontinue treatment.
In preclinical testing, a single injection of BRP reduced food intake by up to 50 percent within one hour. When administered daily to obese mice over a two-week period, the animals lost an average of three grams of body weight, with the reduction coming primarily from fat rather than lean muscle mass. That distinction is particularly significant given ongoing concerns about muscle wasting associated with existing GLP-1 medications.
The peptide was identified with the help of artificial intelligence tools that screened molecular candidates for brain-penetrating properties and receptor selectivity. While human trials have not yet begun, the researchers believe BRP's favorable side-effect profile in animals makes it a strong candidate for clinical development.
Source: ScienceDaily
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.